Healthcare Equipment and Supplies
Company Overview of TransMedics, Inc.
TransMedics, Inc., a medical device company, develops and provides portable warm blood perfusion system that allows for living organ transplant. It offers OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in Europe and Australia. TransMedics, Inc. was founded in 1998 and i...
200 Minuteman Road
Andover, MA 01810
Founded in 1998
Key Executives for TransMedics, Inc.
Founder, Chief Executive Officer, President and Director
Vice President of Operations
Vice President of Business Development
Compensation as of Fiscal Year 2015.
TransMedics, Inc. Key Developments
TransMedics, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 03:00 PM
Oct 31 15
TransMedics, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 03:00 PM. Venue: Westin Grand Central, New York, New York, United States.
TransMedics, Inc. Announces Final Results of The PROCEED II Heart FDA Pivotal Trial at ISHLT
Apr 14 14
TransMedics, Inc. announced that the PROCEED II heart transplant Food and Drug Administration pivotal trial results using the Organ Care System - Heart platform were announced on Saturday, April 12, 2014 at the International Society for Heart and Lung Transplantation 34th Annual Meeting and Scientific Sessions in San Diego, Calif. The OCS Heart PROCEED II FDA pivotal trial met its success criteria for both the primary effectiveness and safety endpoints by demonstrating that the OCS is as safe and effective as the current standard of care (SOC) in preserving standard donor hearts for transplantation. These results were achieved despite the OCS arm having significantly longer total cross clamp time as compared to SOC. In addition, the data from PROCEED II Trial demonstrated that circulating lactate level of the OCS perfusion could be a useful parameter to evaluate donor hearts status ex-vivo.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 11, 2015
May 29, 2015
Most Searched Private Companies
Sponsored Financial Commentaries